CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 3,700 enrolled
Drug / intervention
Beta-blockers withdrawal +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03498066
NCT03498066Phase 4Completed
CompareCT.gov

Assessment of βeta Blocker Interruption After Uncomplicated mYocardial Infarction on Safety and Symptomatic Cardiac Events Requiring Hospitalization: The AβYSS Study

Assistance Publique - Hôpitaux de Paris·interventional·Posted Apr 13, 2018·Updated Dec 6, 2023

In Brief

A Phase 4 clinical trial evaluating Beta-blockers withdrawal and Continuation of the Betablockers (βB) treatment for Myocardial Infarction. Completed, enrolled 3,700 participants across 1 site.

Detailed Summary

ABYSS is a national, multicenter, randomised, open label trial using the PROBE study design, that will evaluate the non-inferiority of the interruption of ΒB therapy after an uncomplicated MI after six months or more of follow-up compared to the continuation of βB evaluated by the primary endpoint or death, MI, Stroke and rehospitalization for others cardiovascular reasons.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyocardial Infarction
CountriesFrance
CollaboratorsGroupe Hospitalier Pitie-Salpetriere

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedApr 13, 2018
Enrollment StartAug 29, 2018
Primary CompletionOct 31, 2023
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 8.2 years ago

Interventions

Beta-blockers withdrawaldrug

withdrawal of all type of betablockers

Continuation of the Betablockers (βB) treatmentdrug

Use Betablockers treatment